0
Abstract: Poster Presentations |

Laboratory Evaluation of Bi-Flex Mode of the Respironics Pro Bi-Level System FREE TO VIEW

Dean R. Hess, PhD RRT FCCP; William H. Hardy, MPM, RRT
Author and Funding Information

Massachusetts General Hospital, Boston, MA


Chest


Chest. 2003;124(4_MeetingAbstracts):227S-c-228S. doi:10.1378/chest.124.4_MeetingAbstracts.227S-c
Text Size: A A A
Published online

Abstract

PURPOSE:  An issue associated with the use of bi-level ventilation is patient compliance. The purpose of this study was to evaluate the performance of a new bi-level embellishment called Bi-Flex, which allows a small amount of pressure relief at the beginning of exhalation to improve patient compliance.

METHODS:  A 2-chambered lung model was used to simulate spontaneous breathing. Pressure and flow were measured immediately proximal to the lung model. IPAP/EPAP settings of 10/8, 15/10, and 16/6 cm H2O were used with 3 levels of Bi-Flex (0 = no pressure relief, 3 = maximal pressure relief). For each combination of settings, the following exhalation parameters were measured: time for pressure to drop from IPAP to EPAP (Time 1), time of pressure relief below EPAP (Time 2), and maximal pressure drop below EPAP. Summary data are provided for 3 breaths.

RESULTS:  There was a significant decrease in Time 1 as the Bi-Flex level was increased (0.49 ± 0.09 s for setting 0, 0.25 ± 0.02 s for setting 1, 0.17 ± 0.01 s for setting 2, and 0.14 ± 0.03 s for setting 3; P<0.001). There was no significant change in Time 2 as the Bi-Flex level was increased (0.80 ± 0.11 s for setting 1, 0.81 ± 0.12 s for setting 2, 0.90 ± 0.17 s for setting 3; P=0.29). The pressure drop below EPAP was 0.70 ± 0.17 cm H2O for Bi-Flex setting 1, 1.42 ± 0.19 cm H2O for Bi-Flex setting 2, and 2.29 ± 0.11 cm H2O for Bi-Flex setting 3. These results are illustrated in the figure.CONCLUSIONS: Bi-Flex produces a significant pressure relief at the beginning of the exhalation phase.

CLINICAL IMPLICATIONS:  The potential for Bi-Flex to improve patient compliance should be subjected to appropriate clinical study.

DISCLOSURE:  D.R. Hess, Respironics, Inc., grant monies.

Wednesday, October 29, 2003

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543